Navigation Links
CutisPharma Announces Strategic Collaboration with Rite Aid Corporation
Date:7/30/2008

Rite Aid to make available FIRST(R) Unit-of-Use prescription compounding

kits to its stores nationwide through Rite Aid distribution centers

WOBURN, Mass., July 30 /PRNewswire/ -- CutisPharma, Inc., an industry leader in developing products for prescription compounding, announced a partnership with Rite Aid Corporation (NYSE: RAD) that will make its innovative FIRST(R) Unit-of-Use Prescription Compounding Kits available for the approximately 27,000 pharmacists and pharmacy technicians at approximately 5,000 Rite Aid stores nationwide. Rite Aid will carry CutisPharma's FIRST(R) Unit-of-Use Prescription Compounding Kits nationwide in all its distribution centers, assuring constant availability. FIRST(R) products will allow Rite Aid the ability to offer compounding service to their customers and, for pharmacies already providing the service, increase the efficiency of their compounding offerings.

FIRST(R) Unit-of-Use Prescription-Compounding Kits are designed to provide an easy and time- saving solution for pharmacies. The pre-measured, pre- weighed components enable pharmacists to dispense the prescribed dosage accurately every time. A single NDC number assigned for the entire kit for each product greatly simplifies the third-party reimbursement process and reduces audit related adjustments. In addition, use of these kits facilitates compliance with the United States Pharmacopeia (USP) Chapter < 795 >.

"Our FIRST(R) Unit-of-Use compounding kits are user-friendly, save compounding time (by over 70%), and can be compounded by a Rite Aid pharmacist while the patient waits, increasing Rite Aid customer satisfaction and eliminating the need for an extra trip to the pharmacy," said Dr. Indu Muni, Chairman & CEO of CutisPha
'/>"/>

SOURCE CutisPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine news :

1. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
2. Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
3. BrainLAB Announces 510(k) FDA Clearance of Monte Carlo Dose Engine for Stereotactic Radiosurgery and Radiation Therapy
4. Align Technology Announces Second Quarter Fiscal 2008 Results
5. Monogram Announces 2008 Second Quarter Financial Results
6. Webcast Alert: Medial Saude S/A Announces Second Quarter 2008 Earnings Conference Call Webcast
7. The Quantum Group Announces Exclusive Screening of New PWeR(TM) System
8. Burgess Announces Expanded Software Partnership With Health Net
9. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
10. Fast Radios Announces Publication of Two Way Radio Guide for Commercial Customers
11. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 2Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 3Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2Kaiser Permanente Recognized by National Committee for Quality Assurance for Innovative Efforts to Reduce Health Care Disparities 59303 1Kaiser Permanente Recognized by National Committee for Quality Assurance for Innovative Efforts to Reduce Health Care Disparities 59303 2Kaiser Permanente Recognized by National Committee for Quality Assurance for Innovative Efforts to Reduce Health Care Disparities 59303 3Kaiser Permanente Recognized by National Committee for Quality Assurance for Innovative Efforts to Reduce Health Care Disparities 59303 4Laser Spine Institute Helping Patients with Debilitating Back Pain at New Medical Consultation Facilities in Beverly Hills and Fort Lauderdale 59298 1Laser Spine Institute Helping Patients with Debilitating Back Pain at New Medical Consultation Facilities in Beverly Hills and Fort Lauderdale 59298 2Sono Tek Announces Second Quarter Results 5398 1Sono Tek Announces Second Quarter Results 5398 2Sono Tek Announces Second Quarter Results 5398 3